Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Withdrawn × Cholecalciferol × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 1/2 1 Phase 1 1

Status

Completed 5 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma in Situ 1

Interventions

Cyclophosphamide 30 Radiotherapy 21 Cisplatin 20 fludarabine 19 Paclitaxel 17 Nivolumab 16 Magnetic Resonance Spectroscopy 16 fludarabine phosphate 14 Carboplatin 14 pembrolizumab 13 Specimen Handling 13 Gemcitabine 13 Radiation 11 Biopsy 11 Docetaxel 10 Melphalan 9 Filgrastim 9 Etoposide 9 Dexamethasone 9 Cytarabine 9 Radiosurgery 8 Granulocyte Colony-Stimulating Factor 8 Doxorubicin 8 venetoclax 7 trametinib 7 durvalumab 7 Sorafenib 7 Rituximab 7 Pemetrexed 7 Ipilimumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02698293 2022-11-22

PDT Plus Vitamin D3 for Anal Dysplasia

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn

Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon ⚡